Medimmune Limited

Elan Pharma International Limited

Andrew Grier Buchanan

Philip Newton

Feenagh Keyes

Sven Nylander

Tord Inghardt

Mark Penney

Matthieu Chodorge

Ruth Franks

Herren Wu

Ralph Raymond Minter

Vahe Bedian

William Dall'Acqua

Michael A Bowen

Matthew Alexander Sleeman

Philip Bland-Ward

Fraser Welsh

Albert George Thom

Jon Eric Hawkinson

Peter Cariuk

Daniel E Berkowitz

Lewis H Romer

Celia Patricia Hart

Carl Anthony Matthews

Johanna Husmark

Clare Balendran

Deepesh Pandey

Jeffrey Brown

Fumin Chang

Lutz Jermutus

David Fairman

Ross Anthony Stewart

Jonathan Seaman

Joseph Grimsby

Cristina Rondinone

Anthony Celeste

Mathieu Chodorge

Chris Stannard

Mark Terence Liddament

Lutz Ulrich Jochen Wilhelm Jermutus

The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.

Antibodies to ticagrelor and methods of use

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.

Stabilized angiopoietin-2 antibodies and uses thereof

This application provides anti-PCSK9&#x2dc;GLP-1 fusions and methods for use.

Anti-PCSK9-GLP-1 fusions and methods for use

The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders.

Antibodies against PD-1 and uses thereof

Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.

Methods of treating neuropathic pain with specific binding members for NGF

Specific binding members for NGF

A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.

Methods and means relating to protein variants

Protein variants of CTLA-4, which show increased activity compared to wild-type in a cell assay and which exhibit increased stability. Such variants are useful for treatment of disorders whereby attenuation of the T cell response would be beneficial.

CTLA-4 protein variants

Growing community of inventors

Granta Park, United Kingdom

Andrew Grier Buchanan